Research and Markets: Rosuvastatin: Developed by Shionogi Inc - China Investigation Market Report 2010-2019

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/kjjrpn/investigation) has announced the addition of the "Investigation Report on China's Rosuvastatin Market, 2010-2019" report to their offering.

First developed by Shionogi Inc. under the code name S-4522 at the end of 1980s, rosuvastatin (rosuvastatin calcium) along with its development, marketing and sales rights, was transferred to AstraZeneca in June 1998 under the code name of ZD-4522. On November 7th 2002, rosuvastatin got its first approval in the Netherlands and later it was approved by Health Council of Canada and FDA under the trade name of Crestor respectively in Feb. 2003 and on Aug.12, 2003. It is mainly used in the treatment of primary hypercholesterolemia, mixed lipid disorders and pure elevated triglycerides.

Ever since its marketing, rosuvastatin calcium has become a rising star of the statin class with sales value growing fast. In 2012, it even became the best-selling lipid-lowering drug around the world with a sales value of USD 6.2 billion.

Rosuvastatin develops fast after entering China, annual sales value rising from less than CNY 2 million in 2007 to CNY 672 million in 2014 and CAGR during this period reaching up to 139%. Currently, rosuvastatin in the Chinese market mainly come from the following companies: IPR Pharmaceuticals (US), Lunan Better Pharmaceutical Co., Ltd, Nanjing Chia Tai Tianqing, Simcere and Zhejiang Jingxin Pharmaceutical Co., Ltd, among which IPR Pharmaceuticals (US) has the largest market share of 82.5% for sales value in 2014.

The market size of rosuvastatin is expected to keep growing in the next few years in China.

Key Topics Covered:

1 Related Concepts of Rosuvastatin

2 Market Profile of Rosuvastatin in China

3 Survey on Sales Status of Rosuvastatin in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Rosuvastatin in China, 2010-2014

5 Survey on Dosage Forms of Rosuvastatin in China, 2010-2014

6 Reference Price of Rosuvastatin in Chinese Hospitals in 2014

7 Major Manufacturers of Rosuvastatin in Chinese Market, 2010-2014

8 Market Outlook of Rosuvastatin in China, 2015-2019

Companies Mentioned

- Lunan Better Pharmaceutical Co., Ltd

- Nanjing Chia Tai Tianqing

- Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.

- Zhejiang Jingxin Pharmaceutical Co., Ltd

- AstraZeneca plc.

For more information visit http://www.researchandmarkets.com/research/kjjrpn/investigation

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals